New Genes in the Carcinogenesis of Colorectal Cancer

Investigating the Role of SPG20,STK31 Genes in the Carcinogenesis of Colorectal Cancer

Colo rectal cancer is one of the greatest ,mutual malignancies worldwide ,accounting for an estimated 1.3 million new cases and >500,000 mortality ⁄ year . is the fourth leading cause of cancer-associated mortality worldwide with speedily ,cumulative ,occurrence rate in the worldwide

Study Overview

• Status: Unknown
• Conditions: Colo-rectal Cancer
• Intervention / Treatment: Diagnostic test: blood sample

Detailed Description

colo rectal cancer represents a global and local problem, as it is one of the commonest types of cancer all over the world. Globally, Colo rectal cancer in women (9.2% of diagnoses) it is the second most common cause of cancer . it is the third most common in men (10.0%). After lung, stomach, and liver cancer it is the fourth most common cause of cancer death.

Cancer is a multistep procedure resulting from an ongoing accretion of genetic and epigenetic fluctuations to the genome.

Spartin is a protein that in humans is encoded by the SPG20 gene. This protein may be involved in endosomal trafficking, microtubule dynamics, or both functions. Aberrant promoter methylation of genes is a common epigenetic alteration in colo rectal cancer .

This has stimulated the prospect to implement a dependable, reasonable and simple approach for Colo rectal detection . The SPG20 gene is situated in chromosome band 13q13.3; the SPG20 gene converts the spartin protein, which is a multi functional protein that has formerly been recognized to be complicated in intra cellular epidermal growth factor receptor trading , The serine-threonine kinase 31 (STK31) gene was initially identified through cDNA subtraction as a testis-specific protein kinase gene expressed in mouse spermatogonia . Recently, STK31 has been described as a novel cancer testis (CT) antigen, highly expressed in Gastrointestinal cancer cells (colo rectal, gastric and esophageal cancer), while restricted to testis and fetal brain in normal tissues .

It was found that SPG20 is mutated in Troy er syndrome, an hereditary spastic paraplegia

• Study Type: Observational
• Enrollment (Anticipated): 62

Contacts and Locations

• Study Contact: Name: mariana anwar, M.st; Phone Number: 01012944965; Email: mariana.10@yahoo.com
• Study Contact Backup: Name: Naglaa Idriss; Phone Number: 01003830234; Email: naglaaidriss@hotmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 35 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

patient between 35-65 who are newly diagnosed with colorectal cancer

Description

Inclusion Criteria:

• age between 35-65
• patient with colorectal cancer (at any stage)
• both sex included

Exclusion Criteria:

• pediatric patients
• patient with insufficient data
• cardiac patient
• pregnant women

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
patient with cancer; blood sample will be collected from patient before and after treatment (surgery or chemotherapy)	Diagnostic test: blood sample; Total genomic DNA will be extracted DNA extraction kit using a QIAamp DNA Blood Mini kit .Genetic analysis of both SPG20 &STK31 by RTPCR.
healthy people; blood sample will be collected for comparison	Diagnostic test: blood sample; Total genomic DNA will be extracted DNA extraction kit using a QIAamp DNA Blood Mini kit .Genetic analysis of both SPG20 &STK31 by RTPCR.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
detection of SPG20&STK31 genes	detection of SPG20&STK31 genes and prediction future treatment for colo-rectal cancer	5 months

Collaborators and Investigators

• Sponsor: Assiut University

Study record dates

Study Major Dates

• Study Start (Anticipated): October 1, 2018
• Primary Completion (Anticipated): September 1, 2019
• Study Completion (Anticipated): September 1, 2019

Study Registration Dates

• First Submitted: August 23, 2017
• First Submitted That Met QC Criteria: August 23, 2017
• First Posted (Actual): August 25, 2017

Study Record Updates

• Last Update Posted (Actual): July 26, 2018
• Last Update Submitted That Met QC Criteria: July 24, 2018
• Last Verified: July 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Neoplastic Processes; Carcinogenesis
• Other Study ID Numbers: CRC (NINDS)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No